Amendments to the Claims:

The listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1. (currently amended) A method of treating anorexia nervosa ~~and related clinical syndromes~~ by administering a composition comprising eicosapentaenoic acid (EPA) that is 95% pure in any appropriate form which can be assimilated by the body.

Claim 2. (currently amended) A method of manufacturing a medicament for the treatment of anorexia nervosa ~~and related clinical syndromes~~ comprising the step of utilizing eicosapentaenoic acid (EPA) in any appropriate form which can be assimilated by the body.

Claim 3. (previously presented) The method according to claim 1, in which the EPA is from a natural EPA-containing oil.

Claim 4. (previously presented) The method according to claim 1, in which the EPA is in the form of the free acid, an appropriate salt, a mono-, di-, or triglyceride, a phospholipid, an amide, an ester or any other biologically compatible derivative.

Claim 5. (previously presented) The method according to claim 1, in which the EPA is in the form of the triglyceride or the ethyl ester.

Claim 6. (cancelled)

Claim 7. (currently amended) The method according to claim 1~~6~~, in which the composition contains less than 10% in aggregate and less than 3% individually of docosahexaenoic acid, linoleic acid and arachidonic acid.

Claim 8. (currently amended) The method according to claim 1~~6~~, in which the composition contains less than 5% in aggregate and less than 2% individually of docosahexaenoic acid and linoleic acid.

Claim 9. (currently amended) The method according to claim 7, in which the composition comprises EPA ~~is~~ in the form of the ethyl ester.

Claim 10. (previously presented) The method according to claim 1, in which the EPA is for oral administration in an appropriate pharmaceutical dosage form and is given at a dose between 50 mg and 20 g/day.

Claim 11. (previously presented) The method according to claim 1, in which the EPA is for parenteral, intramuscular or intravenous administration in an appropriate pharmaceutical dosage form.

Claim 12. (currently amended) The method according to claim 1 wherein the EPA is added to a nutritional supplement for patient with AN ~~or related disorders~~, such supplement to be taken orally, or given by enteral tube, or given intravenously.

Claim 13. (previously presented) The method according to claim 10, in which the EPA is given at a dose between 100 mg and 5 g/day.

Claim 14. (previously presented) The method according to claim 10, in which the EPA is given at a dose between 300 mg and 3 g/day.